A Phase 2 interventional study of Docetaxel and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC), sponsored by PharmaMar. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by PharmaMar · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.
Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,300th largest by enrollment of the 2,995 interventional ones that give a count, is one of 101 that started in 2013, is one of 1,078 in phase 2, and was the 1,350th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,368 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,411 · Phase 2 1,591 · Phase 3 382 · Phase 4 13
First in 1990; this study’s year is marked. 101 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 2,995 interventional studies, 100 across the 246 observational. Of the 2,297 that completed or were terminated, 1,053 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,736 of 3,368 have an industry lead sponsor. The 10 most frequent:
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
PharmaMar has 2 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
272 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United States that are under way reach primary completion within a year, 25 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987956Phase 3Medicine Invention Design, IncPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
Add all 272 to your calendar (.ics) → With an account.
Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
A randomized-controlled, three-arm, phase II study of lurbinectedin (PM01183) alone or in combination with gemcitabine and a control arm with docetaxel as second-line treatment in unresectable non-small cell lung cancer (NSCLC)patients to evaluate the antitumor activity as progression-free survival at four months (PFS4) of PM01183 alone or in combination with gemcitabine as using single agent docetaxel as a reference in the control arm as current standard of care and to analyze overall survival (OS), overall survival rate at 1-year (OS12), duration of response (DR), antitumor activity, as response rate (RR), safety and efficacy profiles of PM01183 alone and in combination with gemcitabine, to be preliminary compared with docetaxel, patients' quality of life (QoL), pharmacokinetics (PK) of PM01183, pharmacokinetic/pharmacodynamic (PK/PD)correlation and pharmacogenomics (PGx)to explore potential correlations between clinical outcomes and molecular parameters found in tumor and blood samples
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
Drug: Docetaxel
3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
Drug: Lurbinectedin (PM01183)
800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
Drug: Gemcitabine · Drug: Lurbinectedin (PM01183)
Powder for solution for infusion
Powder for solution for infusion
Powder for concentrate for solution for infusion
Progression-free Survival Rate at Four Months (PFS4)
The rate estimate of the percentage of patients who are alive and progression-free at 16 weeks (\~4 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: At month four after patient inclusion
Progression-free Survival
PFS, progression-free survival Progression-free survival (PFS), defined as the time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years
Progression-free Survival Rate at Six Months (PFS6)
The rate estimate of the percentage of patients who are alive and progression-free at 24 weeks (\~6 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
Time frame: At month six after patient inclusion
Overall Response Rate
Overall response rate (ORR) was defined as the percentage of patients with a response, either CR or PR, according to RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Time from the date of randomization until 30±7 days after the last treatment infusion, assessed up to 3 years
Objective Response Per RECIST v.1.1
RECIST, Response Evaluation Criteria In Solid Tumors Complete Response (CR) Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm Partial Response (PR) At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Appearance of new lesions was considered PD Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF) Symptomatic deterioration/death due to progression or treatment discontinuation due to treatment-related toxicity occurred before any appropriate tumor assessments had been performed
Time frame: Time from the date of randomization until 30±7 days after the last treatment infusion, assessed up to 3 years
Duration of Response
Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years
Overall Survival (OS)
Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact
Time frame: From the date of first infusion to the date of death or last contact, up to 12 months after last patient inclusion
Information on Quality of Life (QoL)
The mean QoL scores self-reported by patients using the Lung Cancer Symptom Scale (LCSS) at baseline and after the start of the therapy in visits 3 or 6 (+/- 1 visit) and visit 9 for those patients in maintenance therapy. Higher LCSS scores indicate more severe problems and the scale range is (0-100) Total score was calculated as the mean of the total scores of all nine patient ítems (Appetite, Fatigue, Cough, Dyspnea, Hemoptysis, Pain, Lung cancer symptoms, Normal activities, Global QoL)
Time frame: Baseline, Cycle 3 (~9 weeks), Cycle 6 (~18 weeks) and Cycle 9 (~27 weeks)
69 patients were enrolled between 11/09/2013 and 2/10/2015 at 13 centers. 68 patients were treated: 22 in Arm A, 21 in Arm B, and 25 in Arm C. The first dose of the first cycle was administered on 17/09/2013 and the last dose of the last cycle was administered on 3/11/2016. The last patient, last follow-up was on 24/11/2016
| Milestone | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Started | 22 | 22 | 25 |
| Completed | 0 | 0 | 0 |
| Not completed | 22 | 22 | 25 |
| Withdrew: Progressive disease | 12 | 13 | 10 |
| Withdrew: Treatment-unrelated ae | 1 | 0 | 3 |
| Withdrew: Study termination | 0 | 0 | 1 |
| Withdrew: Physician decision | 5 | 3 | 2 |
| Withdrew: Non-treatmentrelated death | 2 | 2 | 2 |
| Withdrew: No treated | 0 | 1 | 0 |
| Withdrew: Treatment-related ae | 2 | 0 | 4 |
| Withdrew: Consent withdrawn by subject | 0 | 1 | 3 |
| Withdrew: Treatment-related death | 0 | 2 | 0 |
The rate estimate of the percentage of patients who are alive and progression-free at 16 weeks (\~4 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| percentage of participants | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Progression-free Survival Rate at Four Months (PFS4) | 27.3 (10.7 to 50.2) | 15.8 (3.4 to 39.6) | 26.1 (10.2 to 48.4) |
PFS, progression-free survival Progression-free survival (PFS), defined as the time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| months | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Progression-free Survival | 3.1 (1.8 to 4) | 1.9 (1.5 to 3) | 3.3 (1.9 to 5.7) |
The rate estimate of the percentage of patients who are alive and progression-free at 24 weeks (\~6 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.
| percentage of participants | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Progression-free Survival Rate at Six Months (PFS6) | 18.2 (2.1 to 34.3) | 16.7 (0 to 33.9) | 17.5 (0 to 35.2) |
Overall response rate (ORR) was defined as the percentage of patients with a response, either CR or PR, according to RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Overall Response Rate | 9.1 (1.1 to 29.2) | 0 (0 to 17.6) | 17.4 (5.0 to 38.8) |
RECIST, Response Evaluation Criteria In Solid Tumors Complete Response (CR) Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm Partial Response (PR) At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Appearance of new lesions was considered PD Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF) Symptomatic deterioration/death due to progression or treatment discontinuation due to treatment-related toxicity occurred before any appropriate tumor assessments had been performed
| Participants | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| PR | 2 | 0 | 4 |
| SD | 10 | 7 | 11 |
| PD | 8 | 8 | 6 |
| TF | 2 | 4 | 2 |
Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Duration of Response | 1.2 (0.8 to 1.6) | — | 6.1 (2.0 to NA) |
Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact
| months | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Overall Survival (OS) | 9.4 (3.1 to NA) | 5.5 (3.0 to 8.0) | 7.2 (4.5 to 10.6) |
The mean QoL scores self-reported by patients using the Lung Cancer Symptom Scale (LCSS) at baseline and after the start of the therapy in visits 3 or 6 (+/- 1 visit) and visit 9 for those patients in maintenance therapy. Higher LCSS scores indicate more severe problems and the scale range is (0-100) Total score was calculated as the mean of the total scores of all nine patient ítems (Appetite, Fatigue, Cough, Dyspnea, Hemoptysis, Pain, Lung cancer symptoms, Normal activities, Global QoL)
| units on a scale | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Baseline | 27.2 (18.4 to 36.1) | 36.4 (25.0 to 47.7) | 38.1 (27.7 to 48.5) |
| Cycle 3 | 29.5 (14.5 to 44.5) | 32.2 (19.5 to 44.9) | 36.4 (25.4 to 47.5) |
| Cycle 6 | 24.3 (17.4 to 31.1) | 55.4 (NA to NA) | 35.4 (-11.7 to 82.5) |
| Cycle 9 | — | 38.1 (-74.8 to 151.1) | — |
Collected over Participants were assessed through study completion, approximately 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A - Docetaxel | 14/22 (63.6%) | 12/22 (54.5%) | 21/22 (95.5%) |
| B - Lurbinectedin (PM01183) | 17/21 (81%) | 9/21 (42.9%) | 20/21 (95.2%) |
| C - Gemcitabine + Lurbinectedin (PM01183) | 21/25 (84%) | 18/25 (72%) | 25/25 (100%) |
| Event | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/22 | 0/21 | 4/25 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/22 | 3/21 | 1/25 |
| NeutropeniaBlood and lymphatic system disorders | 1/22 | 1/21 | 3/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/22 | 1/21 | 3/25 |
| Platelet count decreasedInvestigations | 0/22 | 2/21 | 1/25 |
| Septic shockInfections and infestations | 2/22 | 0/21 | 0/25 |
| Asthenia/FatigueGeneral disorders | 0/22 | 0/21 | 2/25 |
| Cardiac failureCardiac disorders | 0/22 | 0/21 | 2/25 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/22 | 0/21 | 2/25 |
| ShockVascular disorders | 0/22 | 1/21 | 0/25 |
| Event | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) |
|---|---|---|---|
| Asthenia/FatigueGeneral disorders | 16/22 | 16/21 | 17/25 |
| AnaemiaBlood and lymphatic system disorders | 3/22 | 7/21 | 15/25 |
| NeutropeniaBlood and lymphatic system disorders | 4/22 | 3/21 | 13/25 |
| NauseaGastrointestinal disorders | 2/22 | 6/21 | 13/25 |
| Decreased appetiteMetabolism and nutrition disorders | 2/22 | 10/21 | 8/25 |
| VomitingGastrointestinal disorders | 2/22 | 8/21 | 6/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/22 | 5/21 | 4/25 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/22 | 5/21 | 7/25 |
| PyrexiaGeneral disorders | 7/22 | 5/21 | 7/25 |
| Abdominal painGastrointestinal disorders | 0/22 | 6/21 | 3/25 |
69 patients were enrolled between 11/09/2013 and 2/10/2015 at 13 centers. 68 patients were treated: 22 in Arm A, 21 in Arm B, and 25 in Arm C. The first dose of the first cycle was administered on 17/09/2013 and the last dose of the last cycle was administered on 3/11/2016. The last patient, last follow-up was on 24/11/2016
| Age, Categorical(Participants) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 10 | 13 | 38 |
| >=65 years | 7 | 12 | 12 | 31 |
| Age, Continuous(years) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| Median | 61.5 (49 to 72) | 65 (46 to 74) | 64 (41 to 75) | 63 (41 to 75) |
| Sex: Female, Male(Participants) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| Female | 5 | 5 | 9 | 19 |
| Male | 17 | 17 | 16 | 50 |
| Race/Ethnicity, Customized(Participants) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| Race — Caucasian | 21 | 22 | 25 | 68 |
| Race — Unknown | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| United States | 2 | 0 | 0 | 2 |
| Italy | 8 | 11 | 13 | 32 |
| Belgium | 0 | 3 | 0 | 3 |
| Spain | 12 | 8 | 12 | 32 |
| ECOG PS(Participants) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| PS 0 | 6 | 11 | 10 | 27 |
| PS 1 | 16 | 11 | 15 | 42 |
| Histology type(Participants) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| Non-squamous-cell | 17 | 18 | 19 | 54 |
| Squamous-cell | 4 | 4 | 6 | 14 |
| Not specified | 1 | 0 | 0 | 1 |
| Histology grade(Participants) | A - Docetaxel | B - Lurbinectedin (PM01183) | C - Gemcitabine + Lurbinectedin (PM01183) | Total |
|---|---|---|---|---|
| Well differentiated | 0 | 1 | 0 | 1 |
| Moderately differentiated | 2 | 5 | 1 | 8 |
| Poorly differentiated | 7 | 3 | 9 | 19 |
| Unknown | 13 | 13 | 15 | 41 |
15 further baseline measures are reported on the registry.
Ran from Sep 2013 to primary completion in Nov 2016, 38 months.
Results were first posted in Sep 2019, 2 years 10 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 38 months is close to that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183
Carcinoma, Non-Small-Cell Lung →